VWF and thrombotic thrombocytopenic purpura: Thrombotic thrombocytopenic purpura (TTP) was the first pathology to benefit from therapeutic treatment with a NB: in 2019, Caplacizumab (ALX-0681), designed to target the von Willebrand factor, was granted approval by the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) for the treatment of TTP [34].